Jang JY, et al. - Whether or not neoadjuvant treatment enhances survival in patients with borderline resectable pancreatic cancer (BRPC) was determined. They enrolled and randomly assigned 110 patients with BRPC to gemcitabine-based neoadjuvant chemoradiation treatment (54 Gray external beam radiation) followed by surgery or upfront surgery followed by chemoradiation treatment from four large-volume centers in Korea. This is the first prospective randomized controlled trial demonstrating neoadjuvant chemoradiation vs upfront surgery provides oncological benefits in patients with BRPC.